全文获取类型
收费全文 | 19376篇 |
免费 | 1305篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 350篇 |
儿科学 | 525篇 |
妇产科学 | 336篇 |
基础医学 | 2781篇 |
口腔科学 | 484篇 |
临床医学 | 1675篇 |
内科学 | 4032篇 |
皮肤病学 | 457篇 |
神经病学 | 1698篇 |
特种医学 | 1047篇 |
外国民族医学 | 10篇 |
外科学 | 2804篇 |
综合类 | 134篇 |
一般理论 | 5篇 |
预防医学 | 1400篇 |
眼科学 | 330篇 |
药学 | 1307篇 |
中国医学 | 28篇 |
肿瘤学 | 1323篇 |
出版年
2022年 | 148篇 |
2021年 | 365篇 |
2020年 | 215篇 |
2019年 | 320篇 |
2018年 | 420篇 |
2017年 | 327篇 |
2016年 | 395篇 |
2015年 | 437篇 |
2014年 | 526篇 |
2013年 | 669篇 |
2012年 | 1020篇 |
2011年 | 1031篇 |
2010年 | 564篇 |
2009年 | 588篇 |
2008年 | 942篇 |
2007年 | 925篇 |
2006年 | 918篇 |
2005年 | 940篇 |
2004年 | 833篇 |
2003年 | 801篇 |
2002年 | 753篇 |
2001年 | 625篇 |
2000年 | 617篇 |
1999年 | 550篇 |
1998年 | 239篇 |
1997年 | 186篇 |
1996年 | 163篇 |
1995年 | 142篇 |
1994年 | 133篇 |
1993年 | 130篇 |
1992年 | 334篇 |
1991年 | 306篇 |
1990年 | 332篇 |
1989年 | 305篇 |
1988年 | 269篇 |
1987年 | 256篇 |
1986年 | 240篇 |
1985年 | 231篇 |
1984年 | 200篇 |
1983年 | 161篇 |
1982年 | 110篇 |
1981年 | 93篇 |
1979年 | 156篇 |
1978年 | 118篇 |
1977年 | 94篇 |
1975年 | 110篇 |
1974年 | 104篇 |
1973年 | 100篇 |
1970年 | 96篇 |
1969年 | 95篇 |
排序方式: 共有10000条查询结果,搜索用时 390 毫秒
1.
2.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance. 相似文献
3.
4.
5.
Martina A. Steurer Jean Costello Rebecca J. Baer Scott P. Oltman Sky K. Feuer Tania Pacheco-Werner Elizabeth Rogers Marta M. Jankowska Jessica Block Molly McCarthy Matthew S. Pantell Christina Chambers Kelli K. Ryckman Laura L. Jelliffe-Pawlowski 《Paediatric and perinatal epidemiology》2020,34(2):130-138
6.
7.
8.
Dr. R. Hinrichs L. Weber K. Scharffetter-Kochanek 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(5):455-458
Ohne Zusammenfassung 相似文献
9.
Susan M Domchek Andrea Eisen Kathleen Calzone Jill Stopfer Anne Blackwood Barbara L Weber 《Journal of clinical oncology》2003,21(4):593-601
Breast cancer risk assessment provides an estimation of disease risk that can be used to guide management for women at all levels of risk. In addition, the likelihood that breast cancer risk is due to specific genetic susceptibility (such as BRCA1 or BRCA2 mutations) can be determined. Recent developments have reinforced the clinical importance of breast cancer risk assessment. Tamoxifen chemoprevention as well as prevention studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of developing breast cancer. In addition, specific management strategies are now defined for BRCA1 and BRCA2 mutation carriers. Risk may be assessed as the likelihood of developing breast cancer (using risk assessment models) or as the likelihood of detecting a BRCA1 or BRCA2 mutation (using prior probability models). Each of the models has advantages and disadvantages, and all need to be interpreted in context. We review available risk assessment tools and discuss their application. As illustrated by clinical examples, optimal counseling may require the use of several models, as well as clinical judgment, to provide the most accurate and useful information to women and their families. 相似文献
10.
Hugo Maia Julio Casoy Tania Correia Luís Freitas Kleber Pimentel Célia Athayde Elsimar Coutinho 《Gynecological endocrinology》2006,22(10):547-551
OBJECTIVES: To determine whether aromatase expression in the eutopic endometrium and adenomyotic foci is affected by previous use of oral contraceptives containing gestodene, and to determine whether changes in cyclooxygenase-2 (COX-2) expression occur in adenomyosis during the menstrual cycle. PATIENT AND METHODS: This was a retrospective cohort study carried out in paraffin-embedded endometrial tissue obtained from patients with a histological diagnosis of adenomyosis obtained during the proliferative (n = 25) and luteal (n = 10) phases of the menstrual cycle and following the use of continuous oral contraception with gestodene/ethinyl estradiol (n = 7). COX-2 and aromatase expression were measured in both eutopic endometrium and adenomyotic foci using immunohistochemical methods. RESULTS: Aromatase expression was detected in 80% of the endometrial slices by immunohistochemistry. In positive cases, aromatase was mainly detected in the stromal cells of the eutopic endometrium, whereas in the adenomyotic foci this expression was negative in the majority of the cases. Oral contraceptives containing gestodene, on the other hand, were effective in suppressing aromatase expression in both eutopic and ectopic endometrium. COX-2 expression was detected by immunohistochemistry in the glandular epithelium of both eutopic endometrium and adenomyotic foci and there were no significant changes in its intensity throughout the menstrual cycle. CONCLUSION: Aromatase expression in the eutopic endometrium and adenomyotic foci is suppressed by oral contraceptives containing gestodene. Increased aromatase activity may be responsible for the persistent COX-2 expression during the luteal phase. 相似文献